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Background: Next generation sequencing is helping to overcome limitations in organisms less accessible to
classical or reverse genetic methods by facilitating whole genome mutational analysis studies. One traditionally
intractable group, the Apicomplexa, contains several important pathogenic protozoan parasites, including the
Plasmodium species that cause malaria.
Here we apply whole genome analysis methods to the relatively accessible model apicomplexan, Toxoplasma
gondii, to optimize forward genetic methods for chemical mutagenesis using N-ethyl-N-nitrosourea (ENU) and
ethylmethane sulfonate (EMS) at varying dosages.
Results: By comparing three different lab-strains we show that spontaneously generated mutations reflect genome
composition, without nucleotide bias. However, the single nucleotide variations (SNVs) are not distributed randomly
over the genome; most of these mutations reside either in non-coding sequence or are silent with respect to
protein coding. This is in contrast to the random genomic distribution of mutations induced by chemical mutagenesis.
Additionally, we report a genome wide transition vs transversion ratio (ti/tv) of 0.91 for spontaneous mutations in
Toxoplasma, with a slightly higher rate of 1.20 and 1.06 for variants induced by ENU and EMS respectively. We also
show that in the Toxoplasma system, surprisingly, both ENU and EMS have a proclivity for inducing mutations at A/T
base pairs (78.6% and 69.6%, respectively).
Conclusions: The number of SNVs between related laboratory strains is relatively low and managed by purifying
selection away from changes to amino acid sequence. From an experimental mutagenesis point of view, both ENU
(24.7%) and EMS (29.1%) are more likely to generate variation within exons than would naturally accumulate over time
in culture (19.1%), demonstrating the utility of these approaches for yielding proportionally greater changes to the
amino acid sequence. These results will not only direct the methods of future chemical mutagenesis in Toxoplasma,
but also aid in designing forward genetic approaches in less accessible pathogenic protozoa as well.
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The Apicomplexa comprise important human pathogens
such as the malaria-causing Plasmodium spp. [1] and To-
xoplasma gondii, which can cause life-threatening oppor-
tunistic disease and birth defects [2]. Due to the complex
life cycle of most Apicomplexa, the experimental acces-
sibility of these parasites has been limited. However,
Toxoplasma is a comparatively accessible model for other
apicomplexan parasites [3]. The development of Toxo-
plasma as a forward genetic system was pioneered in the
1970s by Elmer Pfefferkorn, who took advantage of the
ability to culture the asexual tachyzoite life cycle stage in-
definitely in vitro and the parasite’s short generation time
of ~7 hrs. Using mutagenized parasites Pfefferkorn started
to dissect the nucleotide salvage and synthesis pathways
([4,5] reviewed in [6]). In the years since Pfefferkorn’s
original work, chemical mutagenesis and forward genetic
analyses have been successfully applied to various unique
aspects of Toxoplasma biology, including invasion and
egress from the host cell and internal budding, the para-
site’s distinct mode of cell division [6-14].
Full exploitation of the power of Toxoplasma forward
genetics will require a better understanding of the muta-
genic profiles associated with specific mutagenesis pro-
tocols. Pfefferkorn initially used N-ethyl-N-nitrosourea
(ENU) on actively growing intracellular parasites. Efficient
mutagenesis was also obtained through nitrosoguanidine
treatment of extracellular parasites and ethylmethane
sulfonate (EMS) treatment of intracellular parasites [15].
ENU and EMS are both widely used chemical mutagens:
EMS is favored in genetic studies in plants [16], fruit flies
[17] and C. elegans [18], whereas ENU is preferentially
used in mice [19] and zebrafish [20]. The choice of muta-
gen is dependent upon the organism’s DNA composition,
DNA repair pathway efficiencies, and the chemical’s muta-
genic signature. As a rule of thumb, EMS preferentially
results in G/C base pair mutations whereas ENU has a
bias toward A/T base pairs [21-23]. We previously con-
firmed the A/T proclivity of ENU in a single Toxoplasma
mutant [7], but the EMS mutagenic signature is currently
unknown.
Whole genome sequencing (WGS) has been used in
model organisms such as Caenorhabditis elegans [18] and
Saccharomyces cerevisiae [24,25] to identify the numbers
of mutations per genome, the ratio of silent vs. non-silent
mutations, the chance of generating mono-allelic traits
and other genome-wide analyses. By cataloging the muta-
tions in a single genome associated with a specific pheno-
type, these approaches also allow mapping of phenotypic
traits to genomic loci. This has been best explored and de-
fined in C. elegans [18,24,26-29], but there are examples
from zebrafish [30] and S. cerevisiae [25,31] as well. WGS
and analysis of the genome-wide distribution of mutations
are new tools whose power has been recognized in geneticmodel organisms [32]. In developing genetic systems for
non-model organisms, however, this power has not been
fully exploited.
In Toxoplasma, the combination of forward genetics
and WGS has extended Pfefferkorn’s pioneering che-
mical mutagenesis studies to map drug resistance genes
[33,34] and biological phenotypes in invasion and egress
[7,13]. To further the development of the Toxoplasma
genetic system, we previously initiated an optimization
of forward mutagenic protocols [35]. Here we further
exploit the power of WGS to expand on these efforts by
defining the mutagenic profiles of ENU and EMS at
varying dosages. Through the analysis of 1208 single
nucleotide variations (SNVs) spontaneously generated in
Toxoplasma under lab conditions, we also show that
these mutations reflect genome nucleotide composition,
without any bias. Furthermore, we show that both ENU
(369 SNVs) and EMS (158 SNVs) have a proclivity for
inducing mutations at A/T base pairs while also genera-
ting greater proportions of protein code changing SNVs
than those generated spontaneously during in vitro cul-
ture. Finally, we show there are no apparent hot- or
cold-spots within the genome for variations generated
via either in vitro culture or chemical mutagenesis. We
use these insights to design an optimized chemical mu-
tagenesis protocol for forward genetic experiments in
Toxoplasma and potentially other Apicomplexa.
Methods
Parasites
Parasites were maintained by in vitro passage in human
foreskin fibroblasts (HFF cells) [36]. An overview of the
genealogy of these strains is given in Figure 1. All the
strains are derived from the Type I RH Toxoplasma strain
isolated from a 1939 case of toxoplasmic encephalitis [37]
and subsequently cloned and adapted for in vitro culture
in the 1970s [5]. The RH-HXGPRT knock-out strain
(RH-ΔHXGPRT) was generated by homologous recom-
bination and 6-thioxanthine selection in the 1990s [38].
The RH-ΔHXGPRT strain made its way from the Roos lab
to the Boothroyd and Striepen labs, and from there to the
Blader and Gubbels labs, respectively. For the purpose of
this paper these sibling strains are referred to as the
‘B-RH’ and ‘G-RH’ strains. The transgenic 2F line stably
expresses LacZ (β-galactosidase), which was selected for
stable, random genomic integration by phleomycin
through the BLE selectable marker [39]. The 2F line was
recloned around 2000 by Vern Carruthers to make 2F-1
(also referred to as 2F1 [40]). Subsequently, chlorampheni-
col selection for the CAT selectable marker was applied to
stably integrate a tandem YFP expressing plasmid resul-
ting in 2F-1-YFP2 [41]. The number of passages (each
representing ~8 generations) along the journeys of these
strains is unknown, but is likely in the range of 100-1000s.
Figure 1 Lineage overview of the parasite strains used in this study. All are of the Type I genotype, with GT1 the sequenced reference
genome available on ToxoDB.org [48]. The GT1 and RH strains are most likely descendants from the same clone [49]. All sequenced strains and
mutants are outlined by red boxes; all are derived from the RH strain. Drug selections to generate transgenic lines are given between brackets in the
lower box of each line. Mutagen dosage is expressed as the percentages of parasites being killed by mutagen treatment (measured by plaque assays).
Phle: phleomycin; D-HR: double homologous recombination; 6-TX: 6-thioxanthine; Chl: chloramphenicol; FUDR: 5-fluoro-2'-deoxyuridine; HXGPRT:
hypoxanthine-xanthine-guanine-phosphoribosyl transferase.
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Chemical mutagenesis was performed essentially as de-
scribed in [35]. Briefly, a T25 flask of confluent HFFs
was inoculated with 1 ml of freshly lysed T. gondii,
which were allowed to invade and replicate in Ed1 media
for 18–25 hrs at 37°C. Ed1 was replaced with 10 ml of
0.1X Ed1 (diluted in DMEM) and the flasks returned to
37°C for 10 minutes. Intracellular parasites were treated
with the mutagen of choice and the appropriate vehicle
controls for 4 hrs at 37°C. After exposure to mutagen,
parasites were recovered by washing the monolayer 3Xwith cold PBS, scraping and lysing the host cells via
passage through a 26.5G needle and filtration through a
3.0 μm polycarbonate filter. Parasites were recovered by
centrifugation at 1000×g for 10 min and returned to a
new confluent T25 flask. The mutagenized population
was allowed to lyse the monolayer naturally, typically in
5–7 days. Percent killing was determined by serial dilu-
tion of 10,000 mutagenized and vehicle treated parasites
into 6 well plates confluent with HFF cells. After 1 week
of undisturbed growth, wells were stained for the pres-
ence of plaques. Percentages were calculated as a ratio
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control. Following phenotypic selection of mutants, indi-
vidual parasite clones were isolated through serial dilu-
tion in 384 well plates of confluent HFFs. After 7 days,
wells containing only single plaques, as seen through the
microscope, were considered monoclonal populations.
ENU mutants were generated in different genetic back-
grounds at concentrations of ENU in the range of 3–
7 mM (Figure 1; because ENU is unstable, stocks should
be titrated relative to percent killing as described above
[35]). Mutants F-P2, AX-H9, CF-B19, and FE-N3 were
generated by Gubbels and screened for a temperature
sensitive growth defect (permissive and restrictive tem-
peratures were 35°C and 40°C, respectively) [8]; mutants
SBR1-3 were generated by the Blader lab and screened for
resistance against the kinase inhibitor SB505124 [33]. Mu-
tant F-P2 was generated using a 55% killing dose; for all
others a dose inducing 70% killing was used. All mutants
were generated by independent mutagenesis experiments
and therefore represent unique SNV pools. For this study
we resequenced mutant F-P2 with longer reads. We diff-
erentiate the “old” data from the “new” data as o-F-P2 [7]
and n-F-P2. The two DNA isolations were performed two
passages apart, which corresponds to approximately 16
generations.
EMS mutants were obtained at mutagen dosages ran-
ging from 3–10 mM in the G-RH genetic background.
Again, as above, the mutagen was titrated via percent
killing. Mutants E2D2, E3E2, and E4D5 were generated
at 70% killing. E2D2 and E4D5 were screened for resis-
tance against DTT induced egress [42] whereas E3E2
was screened for resistance against the invasion enhan-
cing compound 2 [42,43]. Mutants EMS7.5 and EMS10
were generated using 7.5 and 10 mM EMS, inducing
80% and 90% killing, respectively and screened for resis-
tance against 20 μM FUDR [15]. All EMS mutants were
also generated by independent mutagenesis experiments.Whole genome sequencing
Parasites were collected 24 hrs after complete lysis of the
HFF cell monolayer without further scraping, passed three
times through a 26.5G needle, and filtered through a 3 μm
filter membrane. Harvesting parasites 24 hrs post host cell
lysis, while taking care not to disturb the HFF monolayer,
largely eliminates the 50% host DNA background we previ-
ously observed [7]. Genomic DNA was prepared with the
Qiamp DNA mini kit (Qiagen; Valencia, CA) using the
manufacturer’s protocol for cultured cells. Illumina sequen-
cing of strains 2F-1-YFP2 and o-F-P2 was performed at the
Broad Institute, Cambridge, MA as described in [7] and all
others at the Arthritis & Clinical Immunology Department
of the Oklahoma Medical Research Foundation, Oklahoma
City, OK as described in [33].SNV calling
Methods used here are essentially the same as have been
previously described [7]. FASTQ sequence traces were
aligned to a FASTA reference containing both the Toxo-
plasma gondii GT1 genomic reference v7.0 and the human
genome reference build 37. Alignments were performed
with MOSAIK using -mmp .15, −mhp 100 -act 35 -hs 15.
Variable descriptions and procedures are described in the
documentation V1.0 (available at http://bioinformatics.
bc.edu/marthlab/wiki/index.php/Software) [44]. Variations
were called with FreeBayes using standard parameters as
described in the documentation, software version 0.9.9
[45,46]. The resulting SNV calls for the respective samples
were compared to the SNV calls for its respective parent
sample to identify both variations that were shared between
the two samples and those that were unique to the mutant.
Calls were filtered to remove SNVs with coverage less than
5X in either sample, a P value less than 0.8, and less than
75% allele balance in either samples at that position.
To compare the three parent samples, 2F-1-YFP2,
B-RH, and G-RH, each parent was compared to each of
the other two parents separately as described above, cre-
ating a total of 3 datasets: n-F-P2 vs. B-RH, n-F-P2 vs.
G-RH, and B-RH vs. G-RH (note that n-F-P2 sequence
data was used instead of 2F-1-YFP2 since its coverage is
greater and the error rate and human contamination are
much lower; F-P2 specific mutations [7] were manually
removed after analysis). In each of the samples shared
and unique SNVs from each comparison were pooled to-
gether to create a complete list of variants for each sam-
ple. To create a high confidence unified set for three
samples, the rejected positions for all three comparisons
were pooled and SNV calls that intersected with any
rejected position were removed from the variant lists.
Other computational methods
Circose plots were generated using Circos as described
in [47]. Toxoplasma gene densities were calculated using
GFF data for GT1 v7.0 available from toxodb.org [48].
Percentages were calculated by counting the number
of bases within regions annotated as “gene” in a 100 kb
window.
SNV validation
PCR primers were designed to amplify 250 bp up- and
down-stream of a select number of called mutations (fur-
ther details and primer sequences provided in Additional
file 1: Table S1). Primers were designed using an auto-
mated algorithm that required primers to fit the following
description: total product size of 500 ± 200 base pairs,
primer GC content between 40% and 50%, the 3’ most
base must be either a G or C, of the last five 3’-basepairs
three must be either A or T, and the primer must be
unique within the Toxoplasma genome. Primers are
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found that satisfied the above criteria at that length the
calculations were run again with 19 bases, then 21 bases
and so on. Furthermore, the sense primers were designed
with a 5’ extension composed of the M13 universal primer.
PCR products were amplified from parent and mutant
genomic DNA and analyzed by agarose gel electropho-
resis. PCR bands were extracted from gel and sequenced
using the M13 universal primer.
Results
Sequencing results
Illumina paired-end whole genome sequence reads were
obtained for all strains outlined by red boxes in Figure 1.
Collected reads were aligned to the Toxoplasma GT1
reference strain genome assembly [48]. The GT1 strain
was isolated from goat skeletal muscle and is a Type I
genotype strain closely related to the RH strain, for
which no fully sequenced reference currently exists [49].
Sequences were obtained on different machines in diffe-
rent facilities, producing different read lengths and qua-
lities (Figure 2). Regardless of differences in read length,
genomic coverage was very high with more than 99.5%
of the reference genome covered at a read depth of 10
or greater. Average genome coverage ranged from a
depth of 29 for SBR1 to 119 for n-F-P2. From a practical
perspective it is important to cover as much of the
genome as possible when looking for a causative muta-
tion. Our alignment covers >99.5% of the sequenced
GT1 reference, but because gaps remain in the com-
pleted sequence, parts of the genome might be absent
from our analyses. To assess how much of the genome
may be missing from the reference we identified the
proportions of our total reads that aligned to the 14
chromosomal contigs, to the 365 unplaced contigs orFigure 2 Genomic coverage and quality of sequencing reads. Average
Bar color reflects the Illumina read length used as indicated in the legend.
at least 10-fold is shown as percentage of the complete GT1 reference gen
rate between reads and the reference genome. n-F-P2 [n = new] is a re-seq
o-F-P2 [o = old].were unaligned. Less than 1% of the reads aligned to the
365 unaligned contigs, implying that these contigs do
not account for more than 1% of the true genome. Bet-
ween 2% and 10% of the sequence reads could neither
be aligned to the GT1 reference, nor to the human (host
cell) genome. A significant percentage of unaligned reads
is common and expected in Illumina sequence; these
reads likely represent simple sequencing errors, not sig-
nificantly large missing parts of the RH genome. Pre-
vious studies report alignment percentages from as low
as 70% up to 94% [24,27,50-52]. We therefore estimate
that the 14 complete contigs in the Toxoplasma reference
likely comprise as much as 99% of the true genome.
Whether the remaining 1% represents a true chromo-
somal discrepancy between GT1 and RH is not further
pursued here.
SNV calling
We called SNVs in all samples using FREEBAYES. Our
previous work has shown that numerous areas in the
GT1 reference appear to be either duplicated or assem-
bled incorrectly when compared to our RH strains. This
produces incorrect read alignments and leads to a high
rate of spurious variant calls. As we previously pub-
lished, to filter out potentially spurious SNV calls in
these regions, mutant samples were compared to the
relevant parent line to remove areas that had poor align-
ments in either sample [7]. In that work, after filtering
there were 997 polymorphisms shared between the
o-F-P2 and 2F-1-YFP2 parent, and 33 candidate muta-
tions unique to F-P2. Fifteen of the SNVs removed by
filtering were randomly selected and all were experimen-
tally confirmed as false positives. 31 of 33 mutations called
as unique in mutant F-P2 (using the o-F-P2 data) were
validated by PCR amplification and Sanger sequencing [7].fold genomic coverage for the various strains is plotted as indicated.
In the Table in the lower half the percentage of the genome covered
ome (in all cases over 99.5%). Read quality is reported as the mismatch
uenced sample of the F-P2 mutant with longer read length [7], named
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nated by using the n-F-P2 sequence reads produced for
this study, which are of lower error rate, deeper coverage
and longer read length. For data generated in this study,
we validated a select number of SNV calls in EMS mu-
tants E2D2, E3E2, and E4D5 (Additional file 1: Table S1).
The data for 30 variations identified no false positive calls.
Hence, the false positive rate based on these sets of data is
1 out of 63 SNVs (33 + 30 total tested), which is 1.58%. Al-
though the false positive rate is low, and may represent an
overestimation given that no false positives were con-
firmed in the new dataset, it should be considered in the
interpretation of the presented data.
To identify differences between the three parental
strains each sample was compared against the two other
parent samples. For each strain, the mutations (relative
to the reference) that were found only in that parent
were combined with those mutations shared amongst
the parental strains to create a complete high quality set
of SNVs for that sample. To ensure equal confidence in
the data from all three samples, SNVs occurring at posi-
tions rejected in any of the samples were removed from
all three mutants. This is a more conservative set of calls
than the paired set, as any reduction in coverage in one
sample will affect calls in all three, but ensures an un-
biased comparison between the three samples. The pa-
rent sample 2F-1-YFP2 has by far the highest mismatch
rate and second lowest coverage of all of samples. To
improve the quality of the parent comparison, the well
characterized sample n-F-P2 [7], of which 2F-1-YFP2 is
the parental strain, was substituted and the 31 confirmed
SNVs caused by ENU mutagenesis were removed. SNV
calls and further analyses for all strains and mutants are
available in Additional file 2: Table S2.
Natural variations in non-mutagenized parent laboratory
strains
Reads of the three RH-derived parent strains are analyzed
here: 2F-1-YFP2, B-RH and G-RH (Figure 1). Compared
to GT1, 984 mutations are shared among all three (50 of
these are in the apicoplast genome). In this dataset, the
rate of transitions (i.e. mutations of T/A to C/G and from
G/C to A/T) to transversions (T/A to G/C, T/A to A/T,
G/C to T/A or G/C to C/G) was 0.92 (Figure 3). The ti/tv
rate is unique for each species and possibly reflects the na-
ture of DNA repair activity in the species [53]. Because of
the wobble base pairing of codon and anti-codon in the
ribosome, transitions result in more radical amino acid
changes than transversions [54]. These variations could be
the result of differences between the primary RH and GT1
isolates, but are more likely to have accumulated during
the extensive lab maintenance of the RH strain before
these three parental lines diverged. In addition to the
single nucleotide mutations shared among all three linesin our dataset, the sibling RH-ΔHXGPRT strains share an
additional 85 SNVs not found in 2F-1-YFP2. Beyond this,
B-RH contains 66 completely unique SNVs while G-RH
has 19. 2F-1-YFP differs from the GT1 reference by 54
unique SNVs. When these numbers are compared to the
number of SNVs shared among all three strains (984), this
suggests that of all SNVs at least 54/1038 × 100 = 5.2% for
2F-1-YFP2, (85 + 66)/1135 × 100 = 13.3% for B-RH, and
(85 + 19)/1088 × 100 = 9.6% for G-RH have accumulated
during in vitro growth under lab conditions.
We also assessed the impact of the mutations on protein
coding (Figure 3B). We observed that 14.3% of the shared
variations (141 out of 984) cause a change in amino acid
sequence; either a non-synonymous mutation or the gene-
ration of a non-sense codon. 47 SNVs cause synonymous
mutations. Thus, 19.1% of SNVs caused a mutation within
protein coding sequence (141 + 47 out of 984; Figure 3B).
The differences between the two RH strains have accu-
mulated during laboratory maintenance, as they originate
from the same clonal line [38]. The 85 variations shared
between the B-RH and G-RH strains not found in 2F-1-
YFP2 suggest that either the parent RH strain used to
generate the HXGPRT deletion diverged from the RH
strain used to generate the 2F strain, or that the RH-
ΔHXGPRT strain accumulated a significant number of
mutations before the strain was shared between the Roos
and Boothroyd labs.
ENU mutagenic profile
A single ENU mutant was created at a dose resulting in
55% killing (mutant F-P2) and six mutants were derived
from a 70% killing dose (all other ENUmutants) (Figure 1).
For mutants generated at 70% killing, the number of mu-
tations varies from 23 (SBR2) to 70 (SBR1), with an aver-
age of 56.2 (Figure 4A). SBR2 is a likely outlier in the 70%
set, lying even below the 55% killing data point (32 SNVs).
Omitting SBR2 results in an average of 62.8 SNVs at 70%
killing. In either case, the variability at one of only two
doses prevents a robust correlation between mutagen dos-
age and number of mutations.
When we analyze the bases targeted by ENU we find
that 78.6% of mutations are found at A or T (Figure 4B).
This is quite different from the random nucleotide dis-
tribution observed during in vitro culture where 44.5%
of the SNVs are at A or T (Figure 3D), close to the nat-
ural incidence in the genome (45% A or T) [55]. ENU
mutagenesis generated a ti/tv ratio of 1.2, slightly higher
than observed in the spontaneous mutations (Figure 4B).
EMS mutagenic profile
We generated EMS mutants at dosages inducing 70%,
80% and 90% killing. In order to inform future genetic
studies, we used these data to determine the relationship
between the dose of EMS and the number and type of
Figure 3 Comparison of non-mutagenized parent strains: 2F-1-YFP2, Blader RH-ΔHGXPRT (B-RH) and Gubbels RH-ΔHGXPRT (G-RH).
(A) Venn diagram of shared and unique SNVs between the three strains and the GT1 reference genome. (B) The incidence of various mutations
causing changes in amino acid coding. For 2F-1-YFP2, B-RH, and G-RH the unique SNVs vs GT1 are shown (these correspond to the 54, 66, and
19 SNVs in panel A, respectively). “RH-srd.” refers to all SNVs shared between B-RH and G-RH and “all-srd.” refers to the SNVs shared between all
three lines (these correspond to the and 85 and 984 SNVs in panel A, respectively) Syn.: synonymous; non-syn: non-synonymous. * 50 non-coding
SNVs map to the apicoplast genome. (C-E) The incidence of the various base pair changes (SNVs) in the mutants and groups as indicated. Note
that we used the n-F-P2 reads instead of 2F-1-YFP2 reads in this analysis since the quality is much higher (Figure 2); ENU specific n-F-P2 mutations
were removed from the comparative analysis.
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was very consistent, with 18, 15 and 18 mutations identi-
fied in E2D2, E3E2 and E4D5, respectively. At 80% kil-
ling (mutant EMS7.5) this number increased to 37 SNVs
and further increased to 70 SNVs at 90% killing (mutant
EMS10) (Figure 5A). These data show that the numberof mutations induced by EMS approximately doubles as
killing increases by 10%.
Across all EMS mutants 23.4% of the SNVs repre-
sented non-synonymous mutations (Figure 5A), which
was slightly higher than the 19.8% observed for ENU
mutagenesis (Figure 4A). Thus, both chemical mutagens
Figure 4 ENU generated mutants. (A) The incidence of various SNVs in protein coding regions versus those outside annotated open reading
frames. Syn.: synonymous; non-syn: non-synonymous. The number between brackets is the percentage of mutations in each category. (B) The
incidence of SNVs across all seven ENU mutants in panel A. Mutant F-P2 was generated using a 55% killing dose; for all others a dose inducing
70% killing was used. Mutants F-P2, AX-H9, CF-B19, and FE-N3 were generated by Gubbels; mutants SBR1-3 were generated by the Blader lab.
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relative to the 14.3% observed during long term in vitro
growth (Figure 3B). EMS mutants showed a ti/tv rate of
1.06. This was slightly lower than that of ENU but still
higher than the rate observed for spontaneous muta-
tions. Importantly, although the ti/tv rate is lower, theFigure 5 EMS generated mutants. (A) The incidence of various SNVs in p
frames. Syn.: synonymous; non-syn: non-synonymous. The number betwee
incidence of SNVs across the EMS mutants screened for resistance to pharm
enhancing compound 2 (E3E2) [42,43]. These three mutants were generate
across the EMS mutants screened for resistance against 20 μM FUDR [15]. E
80% and 90% killing, respectively.number of non-synonymous mutations is actually higher
for EMS compared to ENU.
Following mutagenesis, the 80% and 90% killing sam-
ples were selected via induction of resistance to FUDR.
This is a nucleotide analogue of deoxyuridine, and could
therefore potentially have a mutagenic effect. Uracilrotein coding regions versus those outside annotated open reading
n brackets is the percentage of mutations in each category. (B) The
acologically induced egress using DTT (E2D2 and E4D5) or invasion
d using an EMS dosage inducing 70% killing. (C) The incidence of SNVs
MS7.5 and EMS10 were generated using 7.5 and 10 mM EMS, inducing
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fluorodeoxyuridylic acid, a suicide inhibitor of thymidi-
late synthase [6]. It is therefore possible that usage of
FUDR or its metabolic derivatives could result in DNA
mutations that skew the mutagenic profile. As such, we
considered the base preferences for the EMS mutants
separately for those mutants generated in the absence
and presence of FUDR selection (Figure 5B and 5C, re-
spectively). The percentage of mutations found at A/T
bases was 60.8% for mutants generated with EMS alone
(51 total SNVs) and 73.8% for those additionally selected
with FUDR (107 SNVs). The ti/tv ratio in the EMS alone
mutants was 0.8, while for the FUDR selected strains
ti/tv was 1.2. It appears that selection with FUDR may
have the potential to influence the EMS mutagenic pro-
file. However, the subtlety of this effect, combined with
the small sample size means that any effects of FUDR
on the mutagenic profile of our SNV pool are minor.
Therefore, the FUDR treated and untreated EMS muta-
genized samples have been considered together in our
analyses, as the effects of EMS are certain to be the
more significant source of mutations than the selection
with FUDR (an increase in EMS dosage by 10% in killing
rate doubles the number of SNVs regardless of whether
FUDR is present).
Characterization of FUDR resistant parasites
Mutants EMS7.5 and EMS10 represent FUDR resistant
clones identified by screening against 20 μM FUDR. To
more specifically evaluate the FUDR resistant pheno-
types we determined the IC50 value of the EMS mutants
and compared them with the parent RH strain and para-
sites wherein the UPRT locus was genetically deleted
(ΔUPRT). It has been shown that FUDR resistance can
be mediated by mutations in the UPRT gene and that
FUDR resistant mutants have no detectable UPRT acti-
vity [56]. UPRT functions in the pyrimidine salvage path-
way, which is not essential in Toxoplasma because it can
synthesize its own pyrimidines [57]. The FUDR IC50 forFigure 6 FUDR resistant mutants. (A) The resistance of Toxoplasma strain
plaque formation relative to an untreated control. Error bars represent SD f
survival in the presence of 20 μM FUDR. (B) Proposed etiological mutation
HsUPRT and DmUPRT are NP_659489 and CG5537, respectively.wild type parasites is less than 0.3 μM, and for ΔUPRT
the IC50 is 264 μM (Figure 6A), both of which are con-
sistent with data in the literature [10,58]. Mutant
EMS7.5 has an IC50 of 217 μM. Interestingly, mutant
EMS10 has an IC50 of 61 μM, which is several fold less
than the ΔUPRT strain.
When we analyzed the SNVs in the genomes of these
mutants we indeed found a mutation in the UPRT co-
ding sequence in the genome of mutant EMS7.5, which
resulted in an amino acid change at position 98 from
Gly into Glu (Figure 6B). The conserved nature of this
glycine and high level of FUDR resistance in this mutant
supports the conclusion that this is a loss of function
mutation. Unexpectedly, for mutant EMS10 we did not
identify a mutation in the UPRT gene, which may ex-
plain the intermediate IC50 of this clone (see Additional
file 2: Table S2 for complete list of SNVs in EMS10).
While complete mapping of the nature FUDR resistance
in this mutant is beyond the scope of this study, these
findings highlight the power of chemical mutagenesis
and phenotypic screening to identify both expected and
unexpected biological targets.
Genome distribution of mutations
The data assembled here comprise 1208 naturally occur-
ring SNVs (Figure 3A) and 527 chemically induced mu-
tations (369 in the ENU mutants, Figure 4; 158 in the
EMS mutants, Figure 5). Using circos plots we plotted
SNVs on the chromosomes together with the gene den-
sity [59] (Figure 7). Despite this small sample size we an-
alyzed these plots for clusters of variants into so-called
hot- and cold-spots. We reasoned that hot regions could
be low in gene coding sequence and vice versa. Based on
these data we do not observe any obvious hot or cold
spots for either naturally occurring or chemically in-
duced SNVs, and as such we detect no clear correlation
between SNV location and gene density. While we did
not observe signatures of bias at any specific regions of
the genome, we sought to further test the randomness ofs to varying concentrations of FUDR. Survival was determined by
rom 6 independent experiments. Both strains were initially selected for
in UPRT identified in mutant EMS7.5. Genbank accession numbers for
Figure 7 Genome wide distribution of mutations. (A) Circos plot of all mutants and gene density. The Toxoplasma GT1 reference genome is
composed of the 14 chromosomes displayed in the outermost circle. The SNVs shared between all 3 RH parent lines and the GT1 reference are
represented by green dots. Strain and mutant specific variations are represented by black dots and are grouped as either parent lines (yellow) or
by mutant genealogy and mutagen as shown in Figure 1. Gene density was mapped using a sliding window approach with a window size of
100 kb. (B-D) QQ-plot of SNV distances vs. exponential distribution. To test the assumption that mutations are distributed randomly, the inter-SNV
distances (taken from Additional file 2: Table S2) are plotted against the exponential distribution, with λ = 1/mean, using a Quantile-Quantile plot;
B = distances between ENU induced SNVs (N = 368, mean = 159582), C = distances between EMS induced SNVs (N = 144, mean = 359992.3),
D = distances between shared SNVs between the parent strains (N = 968, mean = 61631.86). The solid red line in each plot represents the null
assumption y = x.
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whole. Randomly distributed mutations follow a Poisson
distribution with λ equal to the SNV rate. It thus follows
that the distance between randomly distributed SNVs will
be exponentially distributed with a rate equal to 1/λ [60].
Quantile-Quantile (QQ) plots of the inter-mutational dis-
tances for each sample versus the exponential distributionare plotted in Figure 7B-D. The mutations in the parent
samples accumulated during normal in vitro culture and
have been subject to the selective pressures associated
with that environment for numerous generations. As ex-
pected these variants do not appear randomly distributed,
demonstrated by their divergence from the exponential
distribution (Figure 7D). This indicates that these variants
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derived SNV distributions closely match the theoretical
random distribution (Figure 7B, 7C), indicating that the
induced random mutations are, indeed, randomly dis-
tributed. Using the two-sample Kolmogorov-Smirnov
test for each sample against the assumption of an expo-
nential distribution, ENU has p-value = 0.7107 and EMS
has p-value = 0.8782 indicating that they do follow the
exponential distribution and are thus randomly distri-
buted. The SNVs shared between the parent samples have
a p-value = 2.2e-16 indicating that these mutations are not
exponentially distributed and thus not random. To assure
ourselves that the difference in distribution between the
mutagen-derived SNVs and the in vitro culture derived
SNVs is not due to sample size, we repeatedly down-
sampled the in vitro set to match the number of SNVs in
the two mutagenesis data sets and this did not affect the
conclusions. Overall, these data show that ENU and EMS
induce a random distribution of mutations across all chro-
mosomes, whereas the accumulation of SNVs over time in
cell culture is non-random, consistent with selection.
Discussion
The goal of this study was to better understand the nature
of chemical mutagenesis to make informed decisions in
the fine-tuning of forward genetic studies in Toxoplasma.
Additionally we characterized several other salient effects
of laboratory manipulation on the Toxoplasma genome.
We identified significant variation between the supposedly
identical lab strains passaged in different labs. Relatively
small numbers of completely unique mutations (19–66)
were observed when analyzing individual parent strains.
However, B-RH and G-RH, which are derived from the
same clone, share an additional 85 SNVs not found in the
2F-1-YFP2 strain. These 85 mutations originated before
this line was distributed to different labs. These lab-strains
were generated and separated 10–15 years ago, which
encompasses a variable and unknown number of genera-
tions, preventing us from making an accurate estimate of
the mutation rate per generation.
We identified almost 1,000 variations among three dif-
ferent versions of the lab adapted RH strain as compared
to the reference strain GT1 (Figure 1). This value closely
resembles the number of mutations based on a more limi-
ted data set [61] and our data further validates this num-
ber. The variations observed in the parent strains were
non-randomly distributed across the genome, with a bias
away from coding regions (Figures 3, 7). This is consistent
with the principle of purifying selection, wherein amino
acid changes confer a competitive disadvantage [62]. Our
data shows a genome-wide ti/tv ratio close to 1 for spon-
taneous mutations. No previous reports for ti/tv ratios in
Toxoplasma are available, but this ratio is within the nor-
mal range of ratios seen in other organisms [53,54].We attempted to determine whether the selection of
parasites with different drugs might influence mutagenic
profiles (Figure 1). For instance, 6-TX and FUDR are nu-
cleotide analogs that could result in mutations in the
genome, whereas phleomycin is a validated mutagen in
Toxoplasma, causing double-strand breaks [63]. We were
unable to detect any definitive mutagenic signatures for
any of these drug selections, though a slight decrease in
A/T mutation preference was observed in FUDR selected
mutants. While the A/T% and ti/tv ratio for 2F-1-YFP2
differed from the other lab strains, it is unlikely that this is
due to its selection with phleomycin. Single nucleotide
mutations are not an expected consequence of double
strand break repair. In our initial analysis we did screen
for short indels, however none of the calls reached high
confidence values and none could be experimentally vali-
dated, likely due to the significant divergence between the
RH strain and the GT1 reference. Attempts to include
indels called by the current software package increased
our false positive rate without contributing any valid calls,
and thus indel calling was not used in this analysis. New
software packages, which directly compare mutant and
parent rather than aligning both to the reference such as
NIKS [64] or RUFUS (Farrell, Marth et al., in preparation),
will most likely perform better for indels if the reference is
of low quality.
Interestingly, we detected 50 polymorphisms between
the apicoplast genome of GT1 and the RH strain. Since
the apicoplast genome is contained on 35 kb of circular
DNA [65] this indicates a 100-fold higher spontaneous
mutagenesis rate in the plastid’s genome than in the nu-
clear genome. This may highlight differences in the fidelity
of plastid genome replication or to a unique deployment
of DNA repair enzymes in this organelle. Another possible
explanation for the high rate of mutations observed in the
apicoplast is the polyploidy of the plastid genome. The
relative number of sequence reads mapping to the plastid
suggest 7, 14, and 20 copies of its genome in B-RH, G-RH,
and n-F-P2, respectively. Ploidy of up to 25 N is consistent
with previous reports [66,67], although the variation is
quite wide across strains.
Our finding that ~74% of the EMS mutations are at an
A/T base pair in Toxoplasma (Figure 5) deviates dramat-
ically from the general observation across other systems
where EMS has a GC-biased signature [21-23]. The
mechanism of EMS mutagenic activity is the reaction of
its ethyl group predominantly with guanine and to a
much lower extent with adenine to generate N-alkyl ad-
ducts [68]. During DNA replication, DNA polymerases
frequently place thymine, instead of cytosine, opposite
ethylguanine resulting in transitions. The presence of
3-alkyl-adenine is not immediately mutagenic in mam-
malian cells [69]. It has been suggested that this could
be due to an SOS-like response turned on by cytotoxic
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creased removal of 3-alkyladenine increases the number
of single-strand breaks in DNA, which stalls DNA re-
plication and allows a prolonged time for DNA repair by
the alkyltransferase [69]. It is currently neither known
how Toxoplasma DNA polymerase handles different
kinds of DNA damage, nor whether Toxoplasma mounts
an SOS response in response to DNA damage. Toxo-
plasma possesses two apurinic/apyrimidinic (AP) endo-
nucleases that function in DNA base excision repair:
exonuclease III (TgAPE) and endonuclease IV (TgAPN)
[70] but their activities against ENU or EMS induced
damage have not been determined. Collectively, these
findings indicate that the distinct EMS mutagenic signa-
ture in Toxoplasma is most likely caused by a difference
in DNA repair pathways and suggest that Toxoplasma is
able to repair G-alkylation quite well and A-alkylation
very poorly. The signature of mutagenesis by both EMS
and ENU clearly differs from the accumulation of SNVs
through normal in vitro culture, where the A/T bias
nearly mirrors the 45% A/T composition of the genome
as a whole.
One of the new insights generated here is the relation-
ship between particular dosages of ENU or EMS (as mea-
sured by percent killing) and the total number of resultant
mutations. In the past, estimates of this number have been
made experimentally using pro-drugs like 6-TX and
FUDR targeting the negative selectable markers HXGPRT
and UPRT, respectively [8,11,15]. This led to an estimated
10–100 mutations per genome (65 Mb; haploid) using an
ENU dosage inducing 70% killing, but since it was un-
known which mutations resulted in drug resistance these
estimates were very rough. The data shown here confirm
that these estimates were accurate, as we always observe
less than 100 SNVs per genome at the highest dosage used
(70% ENU killing and 90% EMS killing). This approxi-
mates 1 mutation per Mb, which appears to be the “magic
number” as it is consistently observed in mutagenesis
studies that aim to generate phenotypic mutants across
organisms. This includes ENU mutagenized mice (roughly
1 mutation per Mb [71]), a combination of mutagens in
the yeast Pichia stipites (14 mutations in the 15 Mb
genome [25]), and EMS mutagenesis of the yeast Saccha-
romyces cerevisiae (1 mutation per Mb [72]).
We also generated FUDR resistant mutants in this study
as an internal control for mutagenesis experiments at high
EMS dosages. Mutants EMS7.5 and EMS10 were treated
with 20 μM FUDR to select for mutations in the UPRT
gene (Figures 5, 6). The Gly98 into Glu UPRT mutation in
EMS7.5 is consistent with resistance to FUDR since this
residue lies in β-arm of the dimerization interface, and the
crystal structure indicates that dimerization is required for
substrate binding and enzymatic activity [73]. However, in
mutant EMS10 we did not identify a mutation in UPRT.This mutant is also less resistant to FUDR than the
complete UPRTgene deletion or mutant EMS7.5 (Figure 6),
hinting at a potentially different resistance mechanism.
The list of non-synonymous variations contains many
hypothetical genes, which could potentially be involved in
FUDR resistance, but the list also contains CPSII, which is
the first enzyme in the de novo pyrimidine synthesis path-
way (Lys1327 into Arg). It is known that the cytotoxicity
of FUDR and 5-FU can be pluriform and the details are
poorly understood [74]. Whether the mutation in CPSII
indeed confers FUDR resistance is outside the scope of
the current study and was not further pursued here.
Our data show that chemical mutagenesis with either
ENU or EMS induces mutations randomly distributed
over the genome (Figure 7). From a practical forward
genetic perspective that is the desired situation. Because
of its use in Pfefferkorn’s early experiments, ENU became
the mutagen of choice in Toxoplasma [5]. In this study we
confirm Pfefferkorn’s later findings that efficient muta-
genesis was also obtained with EMS treatment of actively
growing intracellular parasites ([15]; nitrosoguanidine
treatment of extracellular parasites was on par with EMS).
We also show that, compared to ENU, EMS produces a
similar or slightly higher fraction of non-synonymous mu-
tations, which is preferred in chemical mutagenesis exper-
iments for mutant screens. From a practical perspective,
the ideal number of SNVs for genetic studies in Toxo-
plasma is 5–10 non-synonymous mutations per genome
[7,13,33]. To be within this range, the optimal dosage of
EMS based on our data would be an EMS concentration
inducing 80% killing (Figure 5). However, we would like to
note this recommendation is based on only two data
points at 80% and 90% killing causing 9 and 17 non-syno-
nymous mutations, respectively. If for other experimental
considerations ENU should be the preferred mutagen, we
recommend an ENU dosage inducing 60% killing to be
within the 5–10 non-synonymous mutation range.
Conclusions
We successfully applied whole genome sequencing and
mutational profiling methods to Toxoplasma and identi-
fied genome variations acquired during long-term in vitro
culture and upon chemical mutagenesis. Comparison of
the three different lab strains showed that serial passaging
of parasites over 10–15 years has resulted in the accu-
mulation of 50–100 SNVs, predominantly in non-coding
sequence or as silent mutations with respect to amino acid
code. This is the first time we are able to provide insights
on the accumulation of polymorphisms in cultured strains
of T. gondii, which are important variables that could
underlie potential differences in experimental outcome in
different labs. Although the experiments here were not ex-
plicitly designed to detect mutagenic profiles for different
drug selectable markers, a subtle change in A/T bias was
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tants. No such signatures were identified for 6-TX or
phleomycin selection, suggesting any mutagenic effects of
drug selection are minimal in comparison to those gener-
ated by the underlying mutagen.
As in other organisms, the ENU mutagenic profile in
Toxoplasma showed a consistent A/T bias. Interestingly, a
similar A/T bias was observed with EMS, which repre-
sents a stark departure from the neutral or G/C bias com-
monly observed in other systems. This suggests the DNA
repair of EMS damage in Toxoplasma differs from other
well-studied genetic systems. Of importance for the design
and interpretation of forward genetic experiments, we val-
idated that both ENU and EMS induce mutations ran-
domly over the genome. For EMS we observed a slightly
higher rate of non-synonymous point mutations and a
lower rate of mutation in non-coding sequence compared
to ENU. These differences, while subtle, make EMS more
likely to generate coding changes while minimizing non-
coding SNVs that can be challenging to functionally dis-
sect. EMS is therefore a preferable mutagen for forward
genetic experiments where non-synonymous mutations
are the desired outcome. From our experience, an 80%
killing dose of EMS, which yields approximately 35 SNVs,
will cause 5–10 coding changes. Following phenotypic se-
lection, this is a feasible number of genes upon which to
focus. We believe that the insights presented here will not
only be helpful to studies in the relatively well-accessible
Toxoplasma parasite, but will pave the way toward for-
ward genetic studies in less accessible protozoan patho-
gens as well.
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